May 10, 2016 08:40 AM EDT
After several years of unending research to fight world's number one killer, Malaria, scientists and doctors are now down waiting for the two-year countdown to make powerful Malaria vaccines available to public after successfully passing series of exams to prove the its effectively.
Currently, there are no vaccines prescribed to prevent or treat Malaria, in spite of the fact that the disease infects 214 million people annually and kills almost half a million. Since then, research has been fully active in field of finding the treatment for Malaria. Fortunately, the researchers have come up to a new study which reveals an experimental malaria vaccine that can protect adults from Malaria for up to a year, a report from TIME said.
In the journal Nature Medicine published on Monday, although doctors and scientists wants a vaccine that would offer longer protection than that of the recent study, a year length would be the longest ever recorded for a Malaria vaccine effect.
The vaccine is called PfSPZ and developed by the biotech company Sanaria Inc which focuses on Malaria. The study receives help from the University of Maryland School of Medicine researchers and National Institutes of Health scientists, the journal added.
Malaria is spread through mosquitoes infected by a parasite then spread the infection to humans. The symptoms for this disease are characterized by flues and fevers which can unfortunately lead to fatal end. This situation has been tapped to 100 people who never had Malaria to a trial phase. Above 60 volunteers had the experimental vaccine and the rest were not vaccinated. The test was administered differently, some got it intravenously while other got it through injection. Then they were exposed to mosquitoes carrying P. falciparum, an early phase of the malaria parasite, said the journal.
After the tests, volunteers' blood were checked to understand how protected they were from the virus. Ultimately, the vaccine was found out to offer up to a year of protection for 55 percent of the men and women. Thus, before the vaccine can be offered clinically, more research and development has to be done.© 2017 University Herald, All rights reserved. Do not reproduce without permission.